Made available in DSpace on 2014-12-17T14:16:33Z (GMT). No. of bitstreams: 1 DianaQCF_DISSERT.pdf: 1652131 bytes, checksum: 3725280f12290a694c1544f741074448 (MD5) Previous issue date: 2010-05-24 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / The aim of this study was to determine the effects of the use of rosuvastatin in patients with atherosclerosis, in relation to blood parameters of selenium and selenoproteins, and also observe possible changes in gene expression of selenoproteins in these patients. The sample consisted of 27 adult and elderly patients with a clinical diagnosis of coronary artery disease undergoing angioplasty, treated at Natal Hospital Center hospital, Natal, RN. Patients were treated with rosuvastatin 10 mg/day during four months. Anthropometric variables such as body mass index (BMI) and Waist circumference (WC) were measured before and after treatment, as well as lipid profile, blood glucose and liver enzymes (AST and ALT). The diet of the patients was also analyzed using 24-hour diet recall. We analyzed the concentrations of selenium in plasma and erythrocytes, and also the activity of Glutathione Peroxidase and gene expression by Real Time PCR of selenoproteins GPx1, SelP1 and SelN1. Patients had mean age of 61.0 ? 9.4 years, 59.3% were men and 40.7% were women. After four months of treatment there was significant reduction of CA and, according to BMI, most were overweight. The intake of macronutrients, cholesterol, polyunsaturated fatty acids, monounsaturated and saturated was adequate, but the energy and fiber intake was below the recommendations. Regarding the selenium intake was observed a high prevalence of inadequacy. As expected, after treatment with rosuvastatin, a significant reduction in total cholesterol, LDL and glucose, which was not observed for HDL. Selenium concentrations in plasma and erythrocytes showed no changes, keeping within the established cutoffs. We observed a significant increase in GPx enzyme activity and mRNA expression of GPX1 and SEPN1, but not for gene SEPP1. Thus, it was found that treatment with rosuvastatin did not reduce the expression of selenoproteins. More studies are needed to clarify the effects of rosuvastatin on gene expression of selenoproteins in patients with atherosclerosis / Este trabalho tem como objetivo verificar os efeitos do uso da rosuvastatina em pacientes com aterosclerose, em rela??o aos par?metros sangu?neos de sel?nio e selenoprote?nas, bem como observar poss?veis altera??es na express?o g?nica de selenoprote?nas nesses pacientes. A amostra foi constitu?da de 27 pacientes adultos e idosos com o diagn?stico cl?nico de doen?a arterial coronariana submetidos ? angioplastia, atendidos no Natal Hospital Center, Natal, RN. Os pacientes foram tratados com 10mg/dia de rosuvastatina durante 4 meses. Vari?veis antropom?tricas, como ?ndice de Massa Corporal (IMC) e Circunfer?ncia Abdominal (CA), foram medidas antes e ap?s o tratamento, bem como o perfil lip?dico, glicemia e enzimas hep?ticas (AST e ALT). A dieta dos pacientes tamb?m foi analisada utilizando o Recordat?rio alimentar de 24 horas. Foram analisadas as concentra??es do sel?nio no plasma e nos eritr?citos, e tamb?m a atividade da enzima Glutationa Peroxidase e a express?o g?nica por PCR em Tempo Real das selenoprote?nas GPx1, SelP1 e SelN1. Os pacientes apresentaram idade m?dia de 61,0?9,4 anos, sendo 59,3% homens e 40,7% mulheres. Ap?s os quatro meses de tratamento observou-se redu??o significativa da CA e, de acordo com o IMC, a maior parte estava com sobrepeso. A ingest?o dos macronutrientes, colesterol, ?cidos graxos polinsaturados, monoinsaturados e saturados foi adequada, por?m a de energia e fibras estava abaixo das recomenda??es. Com rela??o a ingest?o de sel?nio foi observada uma alta preval?ncia de inadequa??o. Como esperado, ap?s o tratamento com a rosuvastatina, houve redu??o significativa do colesterol total e LDL, bem como da glicemia, o que n?o foi observado para o HDL. As concentra??es de sel?nio no plasma e eritr?citos n?o apresentaram altera??es, se mantendo dentro dos pontos de corte estabelecidos. Foi observado um aumento significante na atividade enzim?tica da GPx e na express?o de mRNA do GPX1 e SEPN1, mas n?o para o gene SEPP1. Dessa forma, foi verificado que o tratamento com a rosuvastatina n?o diminuiu a express?o das selenoprote?nas. Mais estudos s?o necess?rios para esclarecer os efeitos da rosuvastatina sobre a express?o g?nica de selenoprote?nas em pacientes com aterosclerose